Investigational ALS Drug Betters Biomarkers, but Can It Improve Motor Functions?

(MedPage Today) -- Tofersen, an investigational antisense oligonucleotide developed to treat an inherited form of amyotrophic lateral sclerosis (ALS), changed biomarkers and curbed neurodegeneration but did not improve motor control and muscle...

Source: MedPage Today Neurology - September 21, 2022 Category: Neurology Source Type: news